Literature DB >> 23690400

The Bordetella pertussis type III secretion system tip complex protein Bsp22 is not a protective antigen and fails to elicit serum antibody responses during infection of humans and mice.

Rodrigo Villarino Romero1, Ilona Bibova, Ondrej Cerny, Branislav Vecerek, Tomas Wald, Oldrich Benada, Jana Zavadilova, Radim Osicka, Peter Sebo.   

Abstract

The type III secretion system (T3SS) of pathogenic bordetellae employs a self-associating tip complex protein Bsp22. This protein is immunogenic during infections by Bordetella bronchiseptica and could be used as a protective antigen to immunize mice against B. bronchiseptica challenge. Since low-passage clinical isolates of the human pathogen Bordetella pertussis produce a highly homologous Bsp22 protein (97% homology), we examined its vaccine and diagnostic potential. No Bsp22-specific antibodies were, however, detected in serum samples from 36 patients with clinically and serologically confirmed whooping cough disease (pertussis syndrome). Moreover, although the induction of Bsp22 secretion by the laboratory-adapted 18323 strain in the course of mice lung infection was observed, the B. pertussis 18323-infected mice did not mount any detectable serum antibody response against Bsp22. Furthermore, immunization with recombinant Bsp22 protein yielded induction of high Bsp22-specific serum antibody titers but did not protect mice against an intranasal challenge with B. pertussis 18323. Unlike for B. bronchiseptica, hence, the Bsp22 protein is nonimmunogenic, and/or the serum antibody response to it is suppressed, during B. pertussis infections of humans and mice.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23690400      PMCID: PMC3719584          DOI: 10.1128/IAI.00353-13

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  40 in total

1.  Bordetella pertussis protein pertactin induces type-specific antibodies: one possible explanation for the emergence of antigenic variants?

Authors:  Qiushui He; Johanna Mäkinen; Guy Berbers; Frits R Mooi; Matti K Viljanen; Heikki Arvilommi; Jussi Mertsola
Journal:  J Infect Dis       Date:  2003-03-26       Impact factor: 5.226

2.  Suppression of serum antibody responses by pertussis toxin after respiratory tract colonization by Bordetella pertussis and identification of an immunodominant lipoprotein.

Authors:  Nicholas H Carbonetti; Galina V Artamonova; Charlotte Andreasen; Edward Dudley; R Michael Mays; Zoe E V Worthington
Journal:  Infect Immun       Date:  2004-06       Impact factor: 3.441

3.  Rapid purification of pertussis toxin (PT) and filamentous hemagglutinin (FHA) by cation-exchange chromatography.

Authors:  Erkan Ozcengiz; Kamer Kilinç; Ozlem Büyüktanir; Ayfer Günalp
Journal:  Vaccine       Date:  2004-03-29       Impact factor: 3.641

4.  Modification of the Polaron sputter-coater unit for glow-discharge activation of carbon support films.

Authors:  O Benada; V Pokorný
Journal:  J Electron Microsc Tech       Date:  1990-11

5.  Roles of the disulfide bond and the carboxy-terminal region of the S1 subunit in the assembly and biosynthesis of pertussis toxin.

Authors:  R Antoine; C Locht
Journal:  Infect Immun       Date:  1990-06       Impact factor: 3.441

6.  A simple chemically defined medium for the production of phase I Bordetella pertussis.

Authors:  D W Stainer; M J Scholte
Journal:  J Gen Microbiol       Date:  1970-10

7.  Role of the polymorphic region 1 of the Bordetella pertussis protein pertactin in immunity.

Authors:  A J King; G Berbers; H F van Oirschot; P Hoogerhout; K Knipping; F R Mooi
Journal:  Microbiology       Date:  2001-11       Impact factor: 2.777

8.  Trends in pertussis among infants in the United States, 1980-1999.

Authors:  Masahiro Tanaka; Charles R Vitek; F Brian Pascual; Kristine M Bisgard; Jacqueline E Tate; Trudy V Murphy
Journal:  JAMA       Date:  2003-12-10       Impact factor: 56.272

9.  Regulation of type III secretion in Bordetella.

Authors:  Seema Mattoo; Ming H Yuk; Lisa L Huang; Jeff F Miller
Journal:  Mol Microbiol       Date:  2004-05       Impact factor: 3.501

10.  Bordetella type III secretion and adenylate cyclase toxin synergize to drive dendritic cells into a semimature state.

Authors:  Jason A Skinner; Annette Reissinger; Hao Shen; Ming H Yuk
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

View more
  9 in total

Review 1.  Bordetella pertussis pathogenesis: current and future challenges.

Authors:  Jeffrey A Melvin; Erich V Scheller; Jeff F Miller; Peggy A Cotter
Journal:  Nat Rev Microbiol       Date:  2014-03-10       Impact factor: 60.633

Review 2.  Bordetella Pertussis virulence factors in the continuing evolution of whooping cough vaccines for improved performance.

Authors:  Dorji Dorji; Frits Mooi; Osvaldo Yantorno; Rajendar Deora; Ross M Graham; Trilochan K Mukkur
Journal:  Med Microbiol Immunol       Date:  2017-11-21       Impact factor: 3.402

Review 3.  Pertussis: Microbiology, Disease, Treatment, and Prevention.

Authors:  Paul E Kilgore; Abdulbaset M Salim; Marcus J Zervos; Heinz-Josef Schmitt
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

4.  Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.

Authors:  Dylan T Boehm; Jesse M Hall; Ting Y Wong; Andrea M DiVenere; Emel Sen-Kilic; Justin R Bevere; Shelby D Bradford; Catherine B Blackwood; Cody M Elkins; Katherine A DeRoos; Mary C Gray; C Garret Cooper; Melinda E Varney; Jennifer A Maynard; Erik L Hewlett; Mariette Barbier; F Heath Damron
Journal:  Infect Immun       Date:  2018-09-21       Impact factor: 3.441

5.  Transcriptional profiling of Bordetella pertussis reveals requirement of RNA chaperone Hfq for Type III secretion system functionality.

Authors:  Ilona Bibova; David Hot; Kristina Keidel; Fabian Amman; Stephanie Slupek; Ondrej Cerny; Roy Gross; Branislav Vecerek
Journal:  RNA Biol       Date:  2015       Impact factor: 4.652

6.  Comparison of the Whole Cell Proteome and Secretome of Epidemic Bordetella pertussis Strains From the 2008-2012 Australian Epidemic Under Sulfate-Modulating Conditions.

Authors:  Laurence Don Wai Luu; Sophie Octavia; Ling Zhong; Mark J Raftery; Vitali Sintchenko; Ruiting Lan
Journal:  Front Microbiol       Date:  2018-11-27       Impact factor: 5.640

7.  Acellular Pertussis Vaccine Inhibits Bordetella pertussis Clearance from the Nasal Mucosa of Mice.

Authors:  Jana Holubová; Ondřej Staněk; Ludmila Brázdilová; Jiří Mašín; Ladislav Bumba; Andrew R Gorringe; Frances Alexander; Peter Šebo
Journal:  Vaccines (Basel)       Date:  2020-11-19

8.  The Fim and FhaB adhesins play a crucial role in nasal cavity infection and Bordetella pertussis transmission in a novel mouse catarrhal infection model.

Authors:  Jana Holubova; Ondrej Stanek; Attila Juhasz; Illiassou Hamidou Soumana; Peter Makovicky; Peter Sebo
Journal:  PLoS Pathog       Date:  2022-04-08       Impact factor: 6.823

Review 9.  Bordetella Type III Secretion Injectosome and Effector Proteins.

Authors:  Jana Kamanova
Journal:  Front Cell Infect Microbiol       Date:  2020-09-04       Impact factor: 5.293

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.